Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.
Anavex Life Sciences says its Alzheimer’s drug candidate Anavex 2-73 may have a role in treating the disease. Data from a long-term extension trial, although small, indicated that the therapy ... Read more
Acadia Pharmaceuticals reports that pimavanserin was particularly effective in treating psychosis in Alzheimer’s disease patients who had severe psychotic symptoms, without triggering a deterioration in their cognition. The information, ... Read more
Researchers may have discovered the reason certain investigational therapies failed in Alzheimer’s disease clinical trials — a finding that could lead to new trials with a greater chance of ... Read more
AgeneBio has obtained a National Institute on Aging grant to conduct a Phase 3 clinical trial of AGB101 (levetiracetam), a compound intended to prevent people with mild memory impairment from developing ... Read more
Pin It on Pinterest